Acta medica Okayama | VOL. 76
Read

Intrathecal Administration of the α1 Adrenergic Antagonist Phentolamine Upregulates Spinal GLT-1 and Improves Mirror Image Pain in SNI Model Rats.

Publication Date Jun 1, 2022

Abstract

Mirror image pain (MIP) is a type of extraterritorial pain that results in contralateral pain or allodynia. Glutamate transporter-1 (GLT-1) is expressed in astrocytes and plays a role in maintaining low glutamate levels in the synaptic cleft. Previous studies have shown that GLT-1 dysfunction induces neuropathic pain. Our previous study revealed bilateral GLT-1 downregulation in the spinal cord of a spared nerve injury (SNI) rat. We hypothesized that spinal GLT-1 is involved in the mechanism of MIP. We also previously demonstrated noradrenergic GLT-1 regulation. Therefore, this study aimed to investigate the effect of an α1 adrenergic antagonist on the development of MIP. Rats were subjected to SNI. Changes in pain behavior and GLT-1 protein levels in the SNI rat spinal cords were then examined by intrathecal administration of the α1 adrenergic antagonist phentolamine, followed by von Frey test and western blotting. SNI resulted in the development of MIP and bilateral downregulation of GLT-1 protein in the rat spinal cord. Intrathecal phentolamine increased contralateral GLT-1 protein levels and partially ameliorated the 50% paw withdrawal threshold in the contralateral hind paw. Spinal GLT-1 upregulation by intrathecal phentolamine ameliorates MIP. GLT-1 plays a role in the development of MIPs.

Concepts

Mirror Image Pain Spared Nerve Injury Glutamate Transporter-1 Glutamate Transporter-1 Protein Levels Changes In Pain Behavior Contralateral Hind Paw Glutamate Transporter-1 Protein Administration Of Phentolamine Von Frey Test Paw Withdrawal Threshold

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Coronavirus Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Introduction: Test solutions (Biotrue, renu Advanced [Bausch and Lomb], ACUVUE RevitaLens [Johnson and Johnson Vision], cleadew [Ophtecs corp.] or AOS...

Read More

Good health Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  2

Patient and public involvement in health care is considered indispensable in the way we conduct daily pediatric neurology practice, and in the develop...

Read More

Quality Of Education Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers prov...

Read More

Gender Equality Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  3

Introduction: As of early March 2022, the COVID-19 pandemic has killed more 5.9 million people worldwide, and infected more than 437 million.

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.